ANI PHARMACEUTICALS, INC Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent
ANI PHARMACEUTICALS, INC (ANIP) reported Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent of 0.00% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities · last filed 2020-02-27
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2019 was 0.00%.
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2018 was 0.00%, a 100.00% decline from fiscal 2017.
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2017 was 8.80%, a 38.89% decline from fiscal 2016.
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2016 was 14.40%, a 171.70% increase from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent 12 month |
|---|---|
| 2019-12-31 | 0.00% 10-K · filed 2020-02-27 |
| 2018-12-31 | 0.00% 10-K · filed 2020-02-27 |
| 2017-12-31 | 8.80% 10-K · filed 2020-02-27 |
| 2016-12-31 | 14.40% 10-K · filed 2019-02-27 |
| 2015-12-31 | 5.30% 10-K · filed 2018-02-27 |
| 2014-12-31 | 0.00% 10-K · filed 2017-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |